VDAC1 and rheumatoid arthritis: It has been found that VDAC can be expressed in the plasma membrane of human osteoclasts and acts as a Cl— channel to regulate the differentiation and function of human osteoclasts, and anti-VDAC antibodies inhibit the formation of human osteoclasts and bone resorption, which can be used for the treatment of diseases with increased bone resorption, such as RA (72).